Gapping up
In reaction to earnings/guidance:
In reaction to earnings/guidance:
- PXLW +6.5%, ANGO +5%, RPM +3.4%, TLRY +2.2%
Other news:
- FRLN +46% (reports initial safety tolerability and enzyme activity data from the ongoing Phase 1/2 GALILEO-1 trial evaluating FLT201 its adeno-associated virus gene therapy candidate in Gaucher disease)
- BROG +15.5% (receives formal acquisition proposal from GULFNAV)
- IGMS +4.9% (Chairman retires)
- FREY +4.4% (surpasses most complex remaining technical hurdle to commence initial fully automated production at the CQP in 4Q 2023)
- ARAY +4.2% (registration dossier for JV system approved by China govt)
- NTRA +3% (Supreme Court denies CDNA request for appeal in patent case with Natera)
- RGNX +2.8% (presents interim clinical data from Phase I/II AFFINITY DUCHENNE trial of RGX-202)
- PLTR +2.8% (closes in on UK NHS contract according to Bloomberg)
- ONON +2.6% (provides three year financial outlook at Investor Day)
- INTC +2% (to separate its Programmable Solutions Group (FPGA) unit into a standalone business)
- ETON +2% (to acquire an abbreviated new drug application for Nitisinone Capsules via Oakrum Pharma's Chapter 11 bankruptcy proceeding)
- STNE +1.7% (authorizes share repurchase program of up to R$300 million in outstanding Class A common shares)
- PACB +1.1% (stock offering by selling shareholders)
- TEVA +1% (Teva Pharma and Sanofi announce exclusive collaboration to deliver inflammatory bowel disease treatment)
Analyst comments:
- ORAN +2.7% (upgraded to Buy from Underperform at BofA Securities)
- MATX +2.2% (upgraded to Outperform from Peer Perform at Wolfe Research)
- RELX +2.2% (upgraded to Buy from Neutral at Goldman)
- LYB +1.2% (upgraded to Buy from Neutral at Citigroup)
- HUBG +1.1% (upgraded to Outperform from Peer Perform at Wolfe Research)
- KEY +1.1% (upgraded to Peer Perform from Underperform at Wolfe Research)